2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 66, n° 4
pages 673-679 (avril 2012)
Doi : 10.1016/j.jaad.2011.08.025

Leflunomide in dermatology

Alan S. Boyd, MD
Departments of Medicine (Dermatology) and Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee 

Reprint requests: Alan S. Boyd, MD, 719 Thompson Ln, Suite 26300, Nashville, TN 37204.

Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This drug inhibits dihydroorotate dehydrogenase, an enzyme critical in the production of intracellular pyrimidines, and down-regulates tumor necrosis factor-alfa activity. Leflunomide has demonstrated usefulness in treating cutaneous psoriasis along with other dermatologic and rheumatologic conditions.

The full text of this article is available in PDF format.

Key words : atopic dermatitis, dihydroorotate dehydrogenase, leflunomide, psoriasis, psoriatic arthritis, rheumatoid arthritis, tumor necrosis factor-alfa

 Funding sources: None.
 Conflicts of interest: None declared.

© 2011  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline